99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical [0.03%]
99%的非酒精性脂肪肝患者符合MASLD标准，因此其自然病程也相同
Hannes Hagström,Johan Vessby,Mattias Ekstedt et al.
Hannes Hagström et al.
Hepatic steatosis aggravates atherosclerosis via small extracellular vesicle-mediated inhibition of cellular cholesterol efflux [0.03%]
肝脂质沉积通过小细胞外囊泡介导的抑制细胞胆固醇流出加重动脉粥样硬化
Xu Chen,Shen Chen,Juan Pang et al.
Xu Chen et al.
Background & aims: While it is recognized that non-alcoholic fatty liver disease (NAFLD) is associated with cardiovascular disease (CVD), how NAFLD affects the development and progression of CVD remains unclear and debata...
Changing from NAFLD through MAFLD to MASLD: Similar prevalence and risk factors in a large Brazilian cohort [0.03%]
从NAFLD通过MAFLD到MASLD的转变：大型巴西队列中的相似患病率和危险因素
Hugo Perazzo,Antonio Guilherme Pacheco,Rosane Härter Griep;Collaborators
Hugo Perazzo
Reply to: "Short-term activation of PERK alleviates the progression of experimental non-alcoholic steatohepatitis" [0.03%]
PERK短期激活可缓解实验性非酒精性脂肪肝病的进展
Qi Wang,Qingfa Bu,Haoming Zhou et al.
Qi Wang et al.
A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis [0.03%]
A+T富集互作域蛋白3A（Arid3a）可抑制胆汁淤积中的Mertk介导的摄取凋亡细胞作用
Ruiling Chen,Bingyuan Huang,Min Lian et al.
Ruiling Chen et al.
Background & aims: Macrophages are key elements in the pathogenesis of cholestatic liver diseases. Arid3a plays a prominent role in the biologic properties of hematopoietic stem cells, B lymphocytes and tumor cells, but i...
Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study [0.03%]
代际队列研究发现不明原因肝硬化在家族中聚集并增加肝癌和不良肝脏结局的风险
Fahim Ebrahimi,Hannes Hagström,Jiangwei Sun et al.
Fahim Ebrahimi et al.
Background & aims: Metabolic dysfunction-associated steatotic liver disease (MASLD; formerly NAFLD) is the fastest growing cause of hepatocellular carcinoma (HCC) worldwide. However, whether family members of individuals ...
Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab [0.03%]
阿特珠单抗/贝伐珠单抗耐药的肝细胞癌和肝胆管癌患者的分子靶向治疗
Wendy Limousin,Pierre Laurent-Puig,Marianne Ziol et al.
Wendy Limousin et al.
Background & aims: The "French Medicine Genomic program 2025" has been designed to give patients with cancers that are refractory to systemic treatments access to off-label therapies adapted to their specific genomic prof...
Prevalence of steatotic liver disease and associated fibrosis in the United States: Results from NHANES 2017-March 2020 [0.03%]
2017年3月至2020年美国非酒精性脂肪肝及其相关纤维化的患病率：基于NHANES数据
Nan Luo,Xuan Zhang,Jingtao Huang et al.
Nan Luo et al.
Uniting to defeat steatotic liver disease: A global mission to promote healthy livers and healthy lives [0.03%]
团结起来战胜脂肪性肝病：促进健康肝脏和健康生活的全球使命
Aleksander Krag,Maria Buti,Jeffrey V Lazarus et al.
Aleksander Krag et al.
Reply to: "Ammonia predicts clinical outcomes in cirrhosis - but there are caveats to consider" [0.03%]
对“氨浓度预测肝硬化临床结果，但需考虑注意事项”的回复
Maria Pilar Ballester,Juan Antonio Carbonell-Asins,Lorenz Balcar et al.
Maria Pilar Ballester et al.